BRAF and neoplasm: MSI-H has been reported to be associated with unique clinicopathologic and molecular features in CRC, including proximal colonic tumor location, mucinous histology, medullary histology, tumor-infiltrating lymphocytes, a peritumoral lymphoid reaction, a Crohn-like lymphoid reaction, the BRAF V600E mutation, resistance to 5-fluorouracil-based adjuvant chemotherapy, and a favorable prognosis [6].